StreetInsider.com News Articles

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced four presentations at the upcoming Annual Meeting of the Endocrine Society (ENDO) being held June 13-16, 2026, in Chicago, IL.

The Company’s presentations at the meeting will include one oral presentation to be made by Huseyin Demirbilek, M.D., Professor, Department of Pediatric Endocrinology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Principal Investigator of the Phase 3

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Thu, 04 Jun 2026 07:30:00 -0400

Rezolute (RZLT) PT Raised to $14 at Maxim Group

Wed, 03 Jun 2026 08:49:33 -0400

Maxim Group analyst Jason McCarthy raised the price target on Rezolute (NASDAQ: RZLT) to $14.00 (from $10.00) while maintaining a Buy rating.

Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald

Wed, 03 Jun 2026 06:50:03 -0400

Cantor Fitzgerald analyst Pete Stavropoulos reiterated a Neutral rating on Rezolute (NASDAQ: RZLT).

The analyst commented, "Interim data from Uplift closely align with the positive outcomes from the Expanded Access Program (EAP) in tumor HI → this clinically de-risks this program and adds to the totality of data for broad utility of ersodetug in HI, including congenital HI (cHI). 6 of the first 8 enrolled patients have met the primary endpoint, defined as achieving ≥50% reduction in IV glucose infusion requirements (GIR) during the 8-wk treatment period. Impressively, all 6 responders completely discontinued IV glucose support following ersodetug treatment. These data

Citizens Upgrades Rezolute (RZLT) to Market Outperform

Tue, 02 Jun 2026 16:53:43 -0400

Citizens analyst Jason Butler upgraded Rezolute (NASDAQ: RZLT) from Market Perform to Market Outperform with a price target of $11.00.

For an analyst ratings summary and ratings history on Rezolute click here. For more ratings news on Rezolute click here.

Shares of Rezolute closed at $3.61 yesterday.

Rezolute (RZLT) PT Raised to $6 at Wedbush

Tue, 02 Jun 2026 15:16:10 -0400

Wedbush analyst Yun Zhong raised the price target on Rezolute (NASDAQ: RZLT) to $6.00 (from $5.00) while maintaining a Outperform rating.

Form 8-K Rezolute, Inc. For: Jun 02

Tue, 02 Jun 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26587323.html

Form 8-K Rezolute, Inc. For: Jun 02

Tue, 02 Jun 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26587323.html

Rezolute reports interim results from phase 3 tumor hyperinsulinism trial

Tue, 02 Jun 2026 07:00:55 -0400

Rezolute Inc. (NASDAQ: RZLT) reported interim data from its phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with six of eight enrolled participants meeting the primary endpoint criterion.

The study has reached 50% enrollment with eight participants enrolled to date, targeting a total of 16 participants with insulinoma and non-islet cell tumor hypoglycemia. Six participants achieved at least a 50% reduction from baseline in intravenous glucose requirements within the eight-week treatment phase, which represents the study's primary endpoint responder criterion.

All six responding participants achieved complete discontinuation of intravenous glucose requirements during ersodetug administration. One participant withdrew from the study before

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Tue, 02 Jun 2026 07:00:00 -0400

Study now 50% enrolled

6 of 8 participants have already met the responder criterion for the study’s primary endpoint

Topline results for the fully enrolled open-label study are expected in the second half of 2026

REDWOOD CITY, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today provided an interim update on its ongoing open-label Phase 3 study (upLIFT) of ersodetug in tumor

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Tue, 02 Jun 2026 07:00:00 -0400

Study now 50% enrolled

6 of 8 participants have already met the responder criterion for the study’s primary endpoint

Topline results for the fully enrolled open-label study are expected in the second half of 2026

Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260515/26498926.html

Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 15 May 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260515/26498926.html

Rezolute (RZLT) PT Raised to $10 at Maxim Group

Thu, 14 May 2026 08:54:02 -0400

Maxim Group analyst Jason McCarthy raised the price target on Rezolute (NASDAQ: RZLT) to $10.00 (from $4.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)

Wed, 13 May 2026 07:53:24 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $5.00 price target on Rezolute (NASDAQ: RZLT).

The analyst commented: "Yesterday, Rezolute reported uneventful 4Q results as the investment community awaits more clarity on ersodetug. Earier this month, the company presented additional analyses from the Phase 3 sunRIZE study of ersodetug in chronic hypoglycemia (cHI) at the PES 2026 conference. These analyses included CGM-derived measures of hypoglycemia burden, weekly hypoglycemia event rates, time spent in the target glucose range, and average weekly glucose levels. (note) In contrast to the primary endpoint, which measured changes in average weekly hypoglycemia events through SMBG,